- Q1 2024 Relmada Therapeutics Inc Earnings Call TranscriptMay 08, 2024€3.54Earnings
- Q4 2023 Relmada Therapeutics Inc Earnings Call TranscriptMar 19, 2024€4.98 (-1.39%)Earnings
- Q3 2023 Relmada Therapeutics Inc Earnings Call TranscriptNov 08, 2023€2.78 (-4.79%)Earnings
- Q2 2023 Relmada Therapeutics Inc Earnings Call TranscriptAug 08, 2023€2.36 (+4.42%)Earnings
- Relmada Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Relmada Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Q1 2023 Relmada Therapeutics Inc Earnings Call TranscriptMay 11, 2023€2.94 (-2.65%)Earnings
- Q4 2022 Relmada Therapeutics Inc Earnings Call TranscriptMar 23, 2023€2.16 (-5.26%)Earnings
- Relmada Therapeutics Inc Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder - Corporate Call TranscriptDec 07, 2022
- Q3 2022 Relmada Therapeutics Inc Earnings Call TranscriptNov 10, 2022€5.9Earnings
- Q2 2022 Relmada Therapeutics Inc Earnings Call TranscriptAug 11, 2022€28 (+6.06%)Earnings
- Relmada Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Q1 2022 Relmada Therapeutics Inc Earnings Call TranscriptMay 05, 2022€22.6 (-3.42%)Earnings
- Q4 2021 Relmada Therapeutics Inc Earnings Call TranscriptMar 23, 2022€21.2 (+8.72%)Earnings
- Relmada Therapeutics Inc Results of Human Abuse Potential Study of REL-1017 vs. Ketamine - Corporate Call TranscriptFeb 23, 2022
- Q3 2021 Relmada Therapeutics Inc Earnings Call TranscriptNov 11, 2021€21.4Earnings
- Relmada Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 10, 2021
- Q2 2021 Relmada Therapeutics Inc Earnings Call TranscriptAug 10, 2021€19 (-3.55%)Earnings
- Relmada Therapeutics Inc REL-1017 Clinical Data Update Call TranscriptJul 27, 2021
- Q1 2021 Relmada Therapeutics Inc Earnings Call TranscriptMay 12, 2021€28.2Earnings
- Q4 2020 Relmada Therapeutics Inc Earnings Call TranscriptMar 23, 2021€29 (+0.17%)Earnings
Relmada Therapeutics Inc Results of Human Abuse Potential Study of REL-1017 vs. Ketamine - Corporate Call Transcript
Good day, and welcome to the Relmada results of the human abuse potential study of REL-1017 versus ketamine call. Today's conference is being recorded. At this time, I would like to turn the conference over to Brian Ritchie of LifeSci Advisors. Please go ahead, sir.
Thank you, operator, and thank you all for joining us this morning. As Slide 2 states, please note that certain information discussed on the call today is covered under the safe harbor provision of the Private Securities Litigation Reform Act. We caution listeners that during this call, Relmada's management team will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in Relmada's press release issued today and the company's SEC filings, including the annual report on Form 10-K and subsequent filings.
This
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)